triple VISTA checkpoint inhibitor/anti-MSLN/IFN beta mutein fusion protein (Abion/Genopharm/Seoul National University/Samsung Medical Center/Sungkyunkwan University)

N/A

Report date: 2025/06/11 10:38:56

Base Information

Drug Nametriple VISTA checkpoint inhibitor/anti-MSLN/IFN beta mutein fusion protein (Abion/Genopharm/Seoul National University/Samsung Medical Center/Sungkyunkwan University)
Drug Alias Nameanti-VISTA/MSLN bispecific antibody fused with IFN beta mutein (Abion/Genopharm/Seoul National University/Samsung Medical Center/Sungkyunkwan University)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionInterferon alpha/beta receptor agonistsV-domain Ig suppressor of T-cell activation inhibitorsImmunostimulants +[5] 
TargetsInterferon alpha/beta receptorV-domain Ig suppressor of T-cell activationMesothelin
Therapy Area/IndicationsMesothelioma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySouth Korea
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesSeoul National University
China Registration ClassN/A

Develop Information

Active CompaniesGenopharm IncSamsung Medical CenterAbion Inc +[5] 
Inactive CompaniesN/A
Active IndicationsMesothelioma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A